Back

Unfavorable systemic and coronary hemodynamic profile of left ventricular hypercontractile phenotype in hypertrophic cardiomyopathy

11 December 2024 (00:00 - 16:00)
Organised by: Logo
Congress Presentation Part of: Imaging to unravel left ventricular hypertrophy Myocardial Disease EACVI Premium Access EuroEcho-Imaging 2024 European Association of Cardiovascular Imaging (EACVI)

About the speaker

Photo
Professor Karina Wierzbowska-Drabik

Medical University of Lodz, Lodz (Poland)

4 More presentations in this session

Presentation thumbnail
Echocardiographic feature analysis for differentiating myocardial hypertrophy etiologies using artificial intelligence
Doctor I. Moon (Bucheon, KR)
Abstract Slides Video
Presentation thumbnail
Sensitivity and specificity of relative apical sparing pattern of global longitudinal strain in the diagnosis of cardiac amyloidosis: a systematic review and meta-analysis
Mr O. Ahmad (SA)
Abstract Slides Video
Presentation thumbnail
Left ventricular mass by three-dimensional echocardiography is associated with myocardial replacement fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy
Doctor V. Rella (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Late gadolinium enhancement prognostic value in hypertrophic cardiomyopathy
Doctor J. Florence (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Imaging to unravel left ventricular hypertrophy
Video

The Event

Event poster

EuroEcho-Imaging 2024

11 December - 13 December 2024
You may be interested in
thumbnail
Congress Presentation
The importance of coronary flow velocity reserve in predicting cardiac mortality and heart failure in hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Left ventricular elastance with resting volumetric transthoracic echocardiography identifies different phenotypes in heart failure with preserved ejection fraction
thumbnail
Congress Presentation
CMR-based assessment of left ventricular hemodynamics in obstructive hypertrophic cardiomyopathy treated with septal reduction therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources